Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

GV-4000 available for licensing

Oct. 18, 1996

Potential new class of neuroleptics discovered at NYU

Oct. 18, 1996

Antipsychotic agents from Asahi Chem.

Oct. 18, 1996

New antimigraine agents disclosed by Merck & Co.

Oct. 18, 1996

Barr re-introduces generic drug for pain

Oct. 18, 1996

Tentative FDA approval for generic analgesic

Oct. 18, 1996

Merck & Co. reveals new series of tachykinin antagonists

Oct. 18, 1996

Yamanouchi's CNS products in the pipeline

Oct. 11, 1996

Novel treatment for chronic fatigue syndrome available in Canada

Oct. 11, 1996

Novel free radical-scavenging and neuroprotective substance isolated by Japanese researchers

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.